NASDAQ:ALKS - Alkermes Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.20
  • Forecasted Upside: -9.09 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.27 (-1.09%)
1 month | 3 months | 12 months
Get New Alkermes Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALKS

Average Price Target: $22.20
▼ -9.09% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $22.20, with a high forecast of $29.00 and a low forecast of $15.00. The average price target represents a -9.09% upside from the last price of $24.42.


The current consensus among 6 investment analysts is to hold stock in Alkermes. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2021HC WainwrightBoost Price TargetNeutral$24.00 ➝ $25.00Low
6/1/2021MizuhoReiterated RatingBuy$29.00High
4/29/2021HC WainwrightBoost Price TargetNeutral$23.00 ➝ $24.00Low
4/26/2021MizuhoBoost Price TargetBuy$28.00 ➝ $29.00High
1/7/2021MizuhoBoost Price Target$24.00 ➝ $28.00N/A
12/11/2020SVB LeerinkBoost Price TargetMarket Perform$18.00 ➝ $23.00Medium
11/10/2020HC WainwrightReiterated RatingHoldLow
10/15/2020MizuhoUpgradeNeutral ➝ Buy$19.00 ➝ $24.00Low
10/7/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2020Bank of AmericaLower Price TargetNeutral$21.00 ➝ $19.00Medium
9/21/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
7/30/2020HC WainwrightReiterated RatingHold$23.00Medium
7/30/2020MizuhoBoost Price TargetNeutral$16.00 ➝ $19.00High
7/30/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$19.00 ➝ $15.00High
4/30/2020HC WainwrightReiterated RatingNeutral$25.00 ➝ $23.00High
4/29/2020Piper SandlerLower Price TargetNeutral$22.00 ➝ $21.00High
4/29/2020Stifel NicolausLower Price TargetAverage ➝ Hold$20.00 ➝ $17.00High
4/29/2020MizuhoReiterated RatingHold$16.00High
4/2/2020Morgan StanleyLower Price TargetEqual Weight$20.00 ➝ $16.00Low
3/23/2020Bank of AmericaLower Price TargetNeutral$20.00 ➝ $17.00Medium
2/14/2020HC WainwrightLower Price TargetNeutral$26.00 ➝ $25.00High
2/14/2020Bank of AmericaDowngradeBuy ➝ Neutral$31.00 ➝ $20.00High
2/14/2020CowenReiterated RatingBuy$28.00High
2/13/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $21.00Low
2/13/2020Stifel NicolausLower Price TargetHold$23.00 ➝ $20.00Low
2/5/2020MizuhoInitiated CoverageNeutral$19.00Medium
1/31/2020Wolfe ResearchUpgradeUnderperform ➝ Peer Perform$21.00Low
1/24/2020SVB LeerinkReiterated RatingMarket PerformLow
1/24/2020CowenReiterated RatingBuyHigh
11/1/2019HC WainwrightLower Price TargetNeutral$28.00 ➝ $26.00Low
10/23/2019Stifel NicolausLower Price TargetHold$25.00 ➝ $23.00High
10/18/2019HC WainwrightReiterated RatingHold$28.00Low
9/13/2019CowenSet Price TargetBuy$34.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$30.00 ➝ $20.00Medium
7/26/2019CitigroupSet Price TargetHold$25.00N/A
7/25/2019Piper Jaffray CompaniesLower Price TargetNeutral$30.00 ➝ $22.00Medium
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$27.00High
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Neutral$28.00 ➝ $28.00High
5/1/2019CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $33.00High
4/26/2019Credit Suisse GroupSet Price TargetSell$28.00Medium
4/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
2/15/2019Credit Suisse GroupUpgradeHold$30.00High
2/15/2019Stifel NicolausLower Price TargetHold$40.00 ➝ $34.00N/A
1/23/2019Cantor FitzgeraldSet Price TargetHold$33.00Low
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
12/18/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$49.00 ➝ $26.00High
12/14/2018Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformMedium
12/13/2018Credit Suisse GroupDowngradeOutperform ➝ Underperform$47.00 ➝ $31.00High
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$36.00Medium
11/5/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$46.00 ➝ $41.00High
11/5/2018Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$40.00Low
11/2/2018Stifel NicolausLower Price TargetHold$44.00 ➝ $40.00High
10/30/2018CowenReiterated RatingBuy$58.00Medium
10/23/2018Cantor FitzgeraldReiterated RatingHold$46.00Low
8/6/2018Stifel NicolausInitiated CoverageHold$45.00Low
7/27/2018Credit Suisse GroupLower Price TargetOutperform ➝ Buy$57.00 ➝ $51.00High
7/27/2018Bank of AmericaLower Price TargetBuy ➝ Buy$56.00 ➝ $54.00High
7/8/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
7/2/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
6/28/2018Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
6/21/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight$67.00 ➝ $42.00High
6/6/2018B. RileyInitiated CoverageBuy$60.00High
5/31/2018CitigroupUpgradeNeutral ➝ BuyMedium
5/16/2018CitigroupUpgradeNeutral ➝ Buy$62.00High
5/11/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$56.00Medium
4/27/2018Credit Suisse GroupSet Price TargetBuy$57.00Low
4/16/2018Credit Suisse GroupSet Price TargetBuy$63.00Medium
4/3/2018JPMorgan Chase & Co.Set Price TargetBuy$63.00High
4/2/2018CowenLower Price TargetOutperform$55.00High
4/2/2018Credit Suisse GroupReiterated RatingBuy$53.00High
4/2/2018Cantor FitzgeraldLower Price TargetNeutral$45.00High
2/23/2018Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$60.00 ➝ $67.00Medium
2/22/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$63.19 ➝ $66.00High
2/20/2018Cantor FitzgeraldReiterated RatingHold$50.00Medium
2/16/2018Credit Suisse GroupBoost Price TargetOutperform$66.00 ➝ $70.00High
2/15/2018CitigroupSet Price TargetHold$62.00High
2/14/2018Credit Suisse GroupSet Price TargetBuy$66.00High
11/28/2017Credit Suisse GroupSet Price TargetBuy$66.00Medium
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/A
10/27/2017UBS GroupSet Price TargetHold$57.00 ➝ $54.00N/A
10/27/2017Credit Suisse GroupLower Price TargetOutperform$70.00 ➝ $66.00N/A
10/26/2017BarclaysSet Price TargetHold$50.00N/A
10/26/2017CitigroupSet Price TargetHold$62.00N/A
10/21/2017MizuhoSet Price TargetBuy$81.00N/A
10/16/2017BarclaysDowngradeOverweight ➝ Equal Weight$66.00 ➝ $50.00N/A
8/25/2017Jefferies Financial GroupSet Price TargetBuy$69.00Low
7/1/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00Low
6/13/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$68.00 ➝ $61.00Medium
6/7/2017Credit Suisse GroupReiterated RatingBuy$70.00Low
5/19/2017Credit Suisse GroupSet Price TargetBuy$70.00Low
4/28/2017CowenReiterated RatingBuyLow
4/27/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00Medium
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00Low
4/3/2017Jefferies Financial GroupReiterated RatingBuy$70.00Medium
3/21/2017CowenReiterated RatingPositive$65.00Low
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00Medium
2/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00N/A
12/21/2016Cantor FitzgeraldReiterated RatingNeutral$52.00N/A
12/15/2016Cantor FitzgeraldInitiated CoverageNeutral$52.00N/A
11/17/2016Jefferies Financial GroupReiterated RatingBuy$70.00N/A
11/2/2016CowenReiterated RatingBuyN/A
10/24/2016UBS GroupSet Price TargetHold$57.00N/A
10/21/2016Morgan StanleyUpgradeUnderweight ➝ Hold$62.00N/A
10/21/2016Jefferies Financial GroupBoost Price TargetBuy$62.00 ➝ $70.00N/A
10/21/2016SVB LeerinkBoost Price TargetOutperform$57.00 ➝ $70.00N/A
10/21/2016Credit Suisse GroupBoost Price TargetOutperform$52.00 ➝ $70.00N/A
10/21/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$51.00 ➝ $78.00N/A
10/20/2016CowenSet Price TargetBuy$60.00N/A
10/4/2016SVB LeerinkInitiated CoverageOutperform$57.00N/A
9/27/2016CitigroupBoost Price TargetNeutral$44.00 ➝ $53.00N/A
9/23/2016CowenReiterated RatingBuyN/A
9/2/2016Morgan StanleyReiterated RatingSell$41.00N/A
7/29/2016JPMorgan Chase & Co.Reiterated RatingHold$51.00N/A
7/29/2016Jefferies Financial GroupBoost Price TargetBuy$54.00 ➝ $62.00N/A
7/29/2016BarclaysBoost Price TargetOverweight$65.00 ➝ $66.00N/A
7/17/2016Jefferies Financial GroupReiterated RatingBuyN/A
7/13/2016BarclaysBoost Price TargetOverweight$50.00 ➝ $65.00N/A
7/12/2016BarclaysReiterated RatingBuy$50.00 ➝ $65.00N/A
6/29/2016UBS GroupReiterated RatingHold$34.00 ➝ $41.00N/A
6/28/2016SVB LeerinkReiterated RatingOutperform$58.00 ➝ $54.00N/A
(Data available from 6/20/2016 forward)
Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $24.42
Low: $24.36
High: $24.62

50 Day Range

MA: $22.27
Low: $18.78
High: $25.15

52 Week Range

Now: $24.42
Low: $15.35
High: $25.47


2,547,234 shs

Average Volume

1,535,330 shs

Market Capitalization

$3.92 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Alkermes?

The following sell-side analysts have issued stock ratings on Alkermes in the last year: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Mizuho, SVB Leerink LLC, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for ALKS.

What is the current price target for Alkermes?

5 Wall Street analysts have set twelve-month price targets for Alkermes in the last year. Their average twelve-month price target is $22.20, suggesting a possible downside of 9.1%. Mizuho has the highest price target set, predicting ALKS will reach $29.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $15.00 for Alkermes in the next year.
View the latest price targets for ALKS.

What is the current consensus analyst rating for Alkermes?

Alkermes currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALKS, but not buy more shares or sell existing shares.
View the latest ratings for ALKS.

What other companies compete with Alkermes?

How do I contact Alkermes' investor relations team?

Alkermes' physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company's listed phone number is 353-1772-8000 and its investor relations email address is [email protected] The official website for Alkermes is